Kira8 (AMG-18) 是一种单选择性IRE1α抑制剂,可以变构减弱IRE1α RNase活性,IC50为 5.9 nM。
生物活性 | Kira8 (AMG-18) is a mono-selectiveIRE1αinhibitor that allosterically attenuatesIRE1α RNase activitywith anIC50of 5.9 nM[1]. |
IC50& Target | IRE1α[1] IC50: 5.9 nM (IRE1α RNase)[1] |
体外研究 (In Vitro) | Kira8 blocks IRE1α oligomerization, and potently inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. Kira8 more potently reduces IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2[1].
|
体内研究 (In Vivo) | MaleIns2+/Akitamice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), significant reduction of hyperglycemia become apparent over several weeks[1]. One week treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) leads to significant reductions in islet XBP1 splicing and TXNIP mRNAs, and preserves Ins1/Ins2, BiP and MANF mRNAs[1].
Animal Model: | MaleIns2+/Akitamice[1] | Dosage: | 50 mg/kg | Administration: | Injected i.p.; daily; for 35 days | Result: | Significant reduction of hyperglycemia became apparent over several weeks. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: Ethanol : 76.92 mg/mL(127.96 mM;ultrasonic and adjust pH to 5 with HCl) DMSO : 65 mg/mL(108.13 mM;Need ultrasonic) H2O : 30 mg/mL(49.91 mM;ultrasonic and warming and adjust pH to 2 with HCl and heat to 60℃) 配制储备液 1 mM | 1.6636 mL | 8.3178 mL | 16.6356 mL | 5 mM | 0.3327 mL | 1.6636 mL | 3.3271 mL | 10 mM | 0.1664 mL | 0.8318 mL | 1.6636 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 4 mg/mL (6.65 mM); Suspended solution; Need ultrasonic
此方案可获得 4 mg/mL (6.65 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 40.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 2. 请依序添加每种溶剂: 3% ethanol, 7%Tween-80, and 90% normal saline Solubility: ≥ 2.31 mg/mL (3.84 mM); Clear solution 3. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.17 mg/mL (3.61 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (3.61 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.17 mg/mL (3.61 mM); Clear solution
此方案可获得 ≥ 2.17 mg/mL (3.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|